Identification of a Series of Tricyclic Natural Products as Potent Broad-Spectrum Inhibitors of Metallo-β-Lactamases

  title={Identification of a Series of Tricyclic Natural Products as Potent Broad-Spectrum Inhibitors of Metallo-$\beta$-Lactamases},
  author={David J. Payne and Juan A. Hueso-Rodr{\'i}guez and Helen F. Boyd and Nestor O. Concha and Cheryl A. Janson and Martin Gilpin and John H. Bateson and Christy Cheever and Nancy Niconovich and Stewart C. Pearson and Stephen F. Rittenhouse and David Tew and Emilio D{\'i}ez and Paloma P{\'e}rez and Jes{\'u}s Angel de la Fuente and Mike Rees and Alfonso Rivera-Sagredo},
  journal={Antimicrobial Agents and Chemotherapy},
  pages={1880 - 1886}
ABSTRACT This work describes the discovery and characterization of a novel series of tricyclic natural product-derived metallo-β-lactamase inhibitors. Natural product screening of the Bacillus cereus II enzyme identified an extract from a strain of Chaetomium funicola with inhibitory activity against metallo-β-lactamases. SB236050, SB238569, and SB236049 were successfully extracted and purified from this extract. The most active of these compounds was SB238569, which possessed Ki values of 79… 
Structural and Kinetic Studies of the Potent Inhibition of Metallo-β-lactamases by 6-Phosphonomethylpyridine-2-carboxylates
There are currently no clinically available inhibitors of metallo-β-lactamases (MBLs), enzymes that hydrolyze β-lactam antibiotics and confer resistance to Gram-negative bacteria. Here we present
Discovery of [1,2,4]Triazole Derivatives as New Metallo-β-Lactamase Inhibitors
This work provided new triazole-based MBL inhibitors and may aid efforts to develop new types of inhibitors combating MBL-mediated resistance.
Comparative study of the inhibition of metallo-beta-lactamases (IMP-1 and VIM-2) by thiol compounds that contain a hydrophobic group.
The relationship between the inhibitory effect of the alkyl chain length was different for both series of inhibitors, suggesting that IMP-1 has a tighter binding site than VIM-2, and QuinolineCnSH did not serve as a fluorescence reagent for metallo-beta-lactamases.
Solution structures of the Bacillus cereus metallo-β-lactamase BcII and its complex with the broad spectrum inhibitor R-thiomandelic acid
Comparisons with other metallo-β-lactamases highlight the roles of individual amino-acid residues in the active site and the β3–β4 loop in inhibitor binding and provide information on the basis of structure–activity relationships among metallo’sβ- lactamase inhibitors.
The 1.5-Å Structure of Chryseobacterium meningosepticum Zinc β-Lactamase in Complex with the Inhibitor, D-Captopril*
The crystal structure of the class-B β-lactamase, BlaB, from the pathogenic bacterium, Chryseobacterium meningosepticum, in complex with the inhibitor, d-captopril, has been solved at 1.5-Å
An Update on the Status of Potent Inhibitors of Metallo-β-Lactamases
In this review, an up-to-date status of the inhibitors investigated for the inhibition of metallo-β-lactamases has been given so that this rich source of structural information of presently known metallo,β, and Lactamase could be helpful in generating a broad-spectrum potent inhibitor of these enzymes.
β-Lactamase Inhibitors Under Research
Intensive research on β-lactamase inhibitors is needed to enlarge the inhibitory spectrum to cover class C and class B enzymes, to overcome the rapid spread of ESBL, and to be prepared for an eventual reduction of activity of existing compounds, such as clavulanic acid.
An Elusive Task: A Clinically Useful Inhibitor of Metallo-β-Lactamases
A critical analysis of the different chemical motifs that had been reported as MBL inhibitors are inspected within the context of mechanistic and structural information with the goal of identifying common aspects that can be used for the development of more efficient and broad-spectrum leads.
Metallo-β-lactamases: structural features, antibiotic recognition, inhibition, and inhibitor design.
This minireview is to summarize the structural features of the metallo-β-lactamases, as well as their antibiotic binding modes and resistance mechanisms, in hopes that the discussion and analysis presented in this paper can stimulate new strategies to overcome the resistance problem and find novel inhibitors.


Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor.
A unique mode of binding of the mercaptocarboxylate inhibitor in the enzyme active site provides a binding model for metallo beta-lactamase inhibition with utility for future drug design.
Inhibition of metallo-beta-lactamases by a series of mercaptoacetic acid thiol ester derivatives
Electrospray mass spectrometry has shown that irreversible inhibition of the Bacillus cereus II metallo-beta-lactamase by SB214751, SB214752, and SB213079 was concomitant with a 90-Da increase in mass of the enzyme.
Biochemical Characterization of the Pseudomonas aeruginosa 101/1477 Metallo-β-Lactamase IMP-1 Produced byEscherichia coli
The blaIMP gene coding for the IMP-1 metallo-β-lactamase produced by a Pseudomonas aeruginosaclinical isolate was overexpressed via a T7 expression system in Escherichia coli BL21(DE3), and its product was purified to homogeneity with a final yield of 35 mg/liter of culture.
Crystal structure of the wide-spectrum binuclear zinc β-lactamase from Bacteroides fragilis
Abstract Background: The metallo-β-lactamase from Bacteroides fragilis hydrolyzes a wide range of β-lactam antibiotics, and is not clinically susceptible to any known β-lactamase inhibitors. B.
Rapid identification of metallo- and serine beta-lactamases
It is concluded that X. maltophilia produces many types of metallo- and serine beta-lactamases distinguishable by these new methods and that the previously reported L-1 and L-2 enzymes are not solely representative of the beta- lactamase produced by this species.
An overview of the kinetic parameters of class B beta-lactamases.
Improved purification methods were devised for the P. maltophilia and A. hydrophila beta-lactamases including, for the latter enzyme, a very efficient affinity chromatography step on a Zn(2+)-chelate column.
beta-lactamase epidemiology and the utility of established and novel beta-lactamase inhibitors
Focus is given to the recent advances in the design of metallo-beta-lactamase inhibitors as these enzymes pose a serious emerging threat to the use of all beta- lactam based therapies.
Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases
Clavulanic acid was a more potent inhibitor than sulbactam for 32 of the 35 plasmid-mediated beta-lactamases tested and was 60 and 580 times more potent than sul bactam against TEM-1 and SHV-1, respectively, currently the two most clinically prevalent gram-negative plasmids in the world.